Every material Form 8-K aTYR PHARMA INC has filed with the SEC since August 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.
Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1
aTyr Pharma reported a third-quarter 2026 net loss of $18.3 million, or $7.43 per share, down from $25.7 million, or $10.60 per share, a year earlier, with no revenue compared with $190,000 in the prior-year quarter. Cash, cash equivalents, restricted cash and investments totaled $50.3 million at September 30, 2026, down from $80.9 million at December 31, 2025, and the company says this funds operations into late 2028. The company is prioritizing strategic partnerships to advance the proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis, which shifts how that program will be funded.
Q3 2026 net loss $18.3 million ($7.43 per share) vs. $25.7 million ($10.60 per share) in Q3 2025
Q3 2026 revenue was zero vs. $190,000 in Q3 2025; R&D expenses $10.4 million and G&A expenses $8.3 million
Cash and investments of $50.3 million at September 30, 2026, vs. $80.9 million at December 31, 2025; runway into late 2028
Reached FDA alignment on the Phase 3 protocol and is prioritizing strategic partnerships and/or licensing arrangements to advance the study
aTyr Pharma said it has reached alignment with the FDA on the protocol for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company expects to start study-related activities in the fourth quarter of 2026 and to focus on regulatory submissions in the U.S. and Europe, but the filing states that future development will require additional capital through equity or debt offerings, grant funding, collaborations, partnerships or licensing.
Planned 54-week, randomized, double-blind, placebo-controlled study of up to approximately 372 patients
Efzofitimod 5.0 mg/kg or placebo given intravenously once every 3 weeks for a total of 17 doses
Primary endpoint is change from baseline in forced vital capacity at week 48; key secondary endpoint is King's Sarcoidosis Questionnaire-Lung score
Study-related activities expected to begin in the fourth quarter of 2026
aTyr Pharma reported a second quarter 2026 net loss of $10.3 million, or $0.11 per share, down from $19.5 million, or $0.22 per share, a year earlier, and announced a workforce reduction of about 60%. The company is focusing its spending on efzofitimod, with cash of $58.9 million at June 30, 2026, which it says will fund operations into late 2028; shareholders face a smaller loss but a shrinking cash balance and leadership changes.
Q2 2026 net loss was $10.3 million, or $0.11 per share, versus $19.5 million, or $0.22 per share, in Q2 2025.
Cash, cash equivalents, restricted cash and investments were $58.9 million at June 30, 2026, down from $80.9 million at December 31, 2025.
CFO Jill Broadfoot steps down September 30, 2026; Brandon Yaras becomes CFO October 1, 2026. General Counsel Nancy Denyes also steps down September 30, 2026.
Restructuring is expected to cut annualized operating expenses by about $13 million beginning in Q4 2026; the company is awaiting FDA comments on its Phase 3 protocol by the end of August 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every aTYR PHARMA INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →